Balance Sheet (Annual)

HRS / Harris Corp. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2012 2013 2014 2015 2016 2017
Assets
  Assets Current
    Cash And Cash Equivalents At Carrying Value 356,000 321,000 561,000 481,000 487,000 484,000
    Receivables Net Current 750,200 696,800 566,100 1,168,000 937,000 623,000
    Inventory Net 617,800 668,700 618,700 1,015,000 964,000 841,000
    Income Taxes Receivable 12,000 36,200 28,100 87,000 62,000 24,000
    Other Assets Current 71,200 77,200 105,200 165,000 144,000 101,000
    Assets Current 2,600,400 1,948,100 1,991,300 3,524,000 2,608,000 2,073,000
  Assets Noncurrent
    Property Plant And Equipment Net 659,400 653,200 728,100 1,165,000 1,015,000 904,000
    Goodwill 1,695,300 1,692,000 1,711,200 6,348,000 5,975,000 5,366,000
    Intangible Assets Net Excluding Goodwill 421,700 308,100 257,500 1,775,000 1,542,000 1,104,000
    Deferred Tax Assets Net Noncurrent 80,300 124,800 87,300 163,000 598,000 409,000
    Other Assets Noncurrent 135,700 132,200 155,800 154,000 258,000 234,000
    Assets Noncurrent 2,992,400 2,910,300 2,939,900 9,605,000 9,388,000 8,017,000
  Assets 5,592,800 4,858,400 4,931,200 13,129,000 11,996,000 10,090,000
Liabilities And Stockholders Equity
  Liabilities Current
    Short Term Borrowings 159,400 144,600 58,300 33,000 15,000 80,000
    Accounts Payable Current 381,000 339,500 324,300 581,000 602,000 540,000
    Employee Related Liabilities Current 229,100 234,300 212,800 255,000 169,000 140,000
    Other Accrued Liabilities Current 269,600 255,800 249,800 518,000 428,000 317,000
    Customer Advances Current 221,500 308,000 265,900 433,000 319,000 252,000
    Accrued Income Taxes Current 12,000 0 - 57,000 11,000 31,000
    Long Term Debt And Capital Lease Obligations Current 4,800 13,400 1,400 130,000 382,000 554,000
    Liabilities Current 1,414,400 1,297,400 1,114,600 2,281,000 1,964,000 1,926,000
  Liabilities Noncurrent
    Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent - - - 1,943,000 2,296,000 1,278,000
    Long Term Debt And Capital Lease Obligations 1,883,000 1,577,100 1,575,800 5,053,000 4,120,000 3,396,000
    Deferred Tax Liabilities Noncurrent - - - - - 34,000
    Other Liabilities Noncurrent 239,800 325,900 331,600 372,000 550,000 507,000
    Liabilities Noncurrent 2,232,300 1,999,800 1,991,200 7,446,000 6,975,000 5,236,000
  Stockholders Equity Including Portion Attributable To Noncontrolling Interest
    Stockholders Equity
      Preferred Stock Value 0 0 0 0 0 0
      Common Stock Value 112,100 106,900 105,500 124,000 125,000 120,000
      Additional Paid In Capital Common Stock 432,800 433,100 509,100 2,031,000 2,096,000 1,741,000
      Retained Earnings Accumulated Deficit 1,416,600 1,079,900 1,226,300 1,258,000 1,330,000 1,343,000
      Accumulated Other Comprehensive Income Loss Net Of Tax -22,600 -58,600 -14,900 -16,000 -495,000 -276,000
      Stockholders Equity 1,938,900 1,561,300 1,826,000 3,397,000 3,056,000 2,928,000
  Liabilities And Stockholders Equity 5,592,800 4,858,400 4,931,200 13,129,000 11,996,000 10,090,000

Peers - Search, Detection, Navigation, Guidance, Aeronautical, and Nautical Systems and Instruments (3812)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 413875105